Literature DB >> 22751498

A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1.

Irma B Stowe1, Ellen L Mercado, Timothy R Stowe, Erika L Bell, Juan A Oses-Prieto, Hilda Hernández, Alma L Burlingame, Frank McCormick.   

Abstract

The Ras/mitogen-activated protein kinase (MAPK) pathway plays a critical role in transducing mitogenic signals from receptor tyrosine kinases. Loss-of-function mutations in one feedback regulator of Ras/MAPK signaling, SPRED1 (Sprouty-related protein with an EVH1 domain), cause Legius syndrome, an autosomal dominant human disorder that resembles Neurofibromatosis-1 (NF1). Spred1 functions as a negative regulator of the Ras/MAPK pathway; however, the underlying molecular mechanism is poorly understood. Here we show that neurofibromin, the NF1 gene product, is a Spred1-interacting protein that is necessary for Spred1's inhibitory function. We show that Spred1 binding induces the plasma membrane localization of NF1, which subsequently down-regulates Ras-GTP levels. This novel mechanism for the regulation of neurofibromin provides a molecular bridge for understanding the overlapping pathophysiology of NF1 and Legius syndrome.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22751498      PMCID: PMC3403010          DOI: 10.1101/gad.190876.112

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  34 in total

1.  The Sprouty-related protein, Spred-1, localizes in a lipid raft/caveola and inhibits ERK activation in collaboration with caveolin-1.

Authors:  Atsushi Nonami; Takaharu Taketomi; Akiko Kimura; Kazuko Saeki; Hiromi Takaki; Takahito Sanada; Koji Taniguchi; Mine Harada; Reiko Kato; Akihiko Yoshimura
Journal:  Genes Cells       Date:  2005-09       Impact factor: 1.891

2.  Distinct requirements for the Sprouty domain for functional activity of Spred proteins.

Authors:  James A J King; Andrew F L Straffon; Giovanna M D'Abaco; Carole L C Poon; Stacey T T I; Craig M Smith; Michael Buchert; Niall M Corcoran; Nathan E Hall; Bernard A Callus; Boris Sarcevic; Daniel Martin; Peter Lock; Christopher M Hovens
Journal:  Biochem J       Date:  2005-06-01       Impact factor: 3.857

3.  1.15 A crystal structure of the X. tropicalis Spred1 EVH1 domain suggests a fourth distinct peptide-binding mechanism within the EVH1 family.

Authors:  Nicholas J Harmer; Jeremy M Sivak; Enrique Amaya; Tom L Blundell
Journal:  FEBS Lett       Date:  2005-02-14       Impact factor: 4.124

4.  Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis.

Authors:  J E DeClue; A G Papageorge; J A Fletcher; S R Diehl; N Ratner; W C Vass; D R Lowy
Journal:  Cell       Date:  1992-04-17       Impact factor: 41.582

5.  Mena, a relative of VASP and Drosophila Enabled, is implicated in the control of microfilament dynamics.

Authors:  F B Gertler; K Niebuhr; M Reinhard; J Wehland; P Soriano
Journal:  Cell       Date:  1996-10-18       Impact factor: 41.582

6.  The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21.

Authors:  G A Martin; D Viskochil; G Bollag; P C McCabe; W J Crosier; H Haubruck; L Conroy; R Clark; P O'Connell; R M Cawthon
Journal:  Cell       Date:  1990-11-16       Impact factor: 41.582

7.  Phosphorylation of neurofibromin by PKC is a possible molecular switch in EGF receptor signaling in neural cells.

Authors:  D Mangoura; Y Sun; C Li; D Singh; D H Gutmann; A Flores; M Ahmed; G Vallianatos
Journal:  Oncogene       Date:  2006-02-02       Impact factor: 9.867

8.  Opposing actions of CSW and RasGAP modulate the strength of Torso RTK signaling in the Drosophila terminal pathway.

Authors:  V Cleghon; P Feldmann; C Ghiglione; T D Copeland; N Perrimon; D A Hughes; D K Morrison
Journal:  Mol Cell       Date:  1998-12       Impact factor: 17.970

9.  Spred-1 negatively regulates interleukin-3-mediated ERK/mitogen-activated protein (MAP) kinase activation in hematopoietic cells.

Authors:  Atsushi Nonami; Reiko Kato; Koji Taniguchi; Daigo Yoshiga; Takaharu Taketomi; Satoru Fukuyama; Mine Harada; Atsuo Sasaki; Akihiko Yoshimura
Journal:  J Biol Chem       Date:  2004-09-30       Impact factor: 5.157

10.  Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells.

Authors:  G Bollag; D W Clapp; S Shih; F Adler; Y Y Zhang; P Thompson; B J Lange; M H Freedman; F McCormick; T Jacks; K Shannon
Journal:  Nat Genet       Date:  1996-02       Impact factor: 38.330

View more
  68 in total

Review 1.  MicroRNA-Based Therapeutic Strategies for Targeting Mutant and Wild Type RAS in Cancer.

Authors:  Sriganesh B Sharma; John Michael Ruppert
Journal:  Drug Dev Res       Date:  2015-08-18       Impact factor: 4.360

Review 2.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

3.  Genetic basis of neurofibromatosis type 1 and related conditions, including mosaicism.

Authors:  Eric Legius; Hilde Brems
Journal:  Childs Nerv Syst       Date:  2020-06-29       Impact factor: 1.475

Review 4.  Tumor adaptation and resistance to RAF inhibitors.

Authors:  Piro Lito; Neal Rosen; David B Solit
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

Review 5.  Ras-Specific GTPase-Activating Proteins-Structures, Mechanisms, and Interactions.

Authors:  Klaus Scheffzek; Giridhar Shivalingaiah
Journal:  Cold Spring Harb Perspect Med       Date:  2019-03-01       Impact factor: 6.915

Review 6.  RAS Proteins and Their Regulators in Human Disease.

Authors:  Dhirendra K Simanshu; Dwight V Nissley; Frank McCormick
Journal:  Cell       Date:  2017-06-29       Impact factor: 41.582

7.  SPRED proteins provide a NF-ty link to Ras suppression.

Authors:  Andrea I McClatchey; Karen Cichowski
Journal:  Genes Dev       Date:  2012-07-15       Impact factor: 11.361

8.  Pathogenetics of the RASopathies.

Authors:  William E Tidyman; Katherine A Rauen
Journal:  Hum Mol Genet       Date:  2016-07-12       Impact factor: 6.150

9.  HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.

Authors:  A Omrani; T van der Vaart; E Mientjes; G M van Woerden; M R Hojjati; K W Li; D H Gutmann; C N Levelt; A B Smit; A J Silva; S A Kushner; Y Elgersma
Journal:  Mol Psychiatry       Date:  2015-04-28       Impact factor: 15.992

Review 10.  Nonredundant functions for Ras GTPase-activating proteins in tissue homeostasis.

Authors:  Philip D King; Beth A Lubeck; Philip E Lapinski
Journal:  Sci Signal       Date:  2013-02-26       Impact factor: 8.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.